Please Wait...

The Latest Developments in Osteoarthritis Imaging

I will be at the 2010 World Congress on Osteoarthritis in Brussels later this week. This conference, organized by the Osteoarthritis Research Society International (OARSI), runs from September 23 to September 29 and is a great opportunity to identify some of the new osteoarthritis imaging work that is going on in the field.

Osteoarthritis (OA) is a common degenerative disease of the joints that is characterized by cartilage breakdown. It affects about 10% of adults in Western countries.  Interestingly last year a work force put together by the FDA to further characterize OA defined it as a disease of the whole joint and not just focused on the cartilage.

One of the areas that I am involved with is the development of imaging techniques that will aid drug development for OA.   The aim is to detect changes in disease progression or regression, so that clinical trials can be done over short periods of time and show drug efficacy in early stages of the disease.

At BioClinica, we collaborate with Chondrometrics to provide cartilage segmentation from MRI scans.  This allows us to generate quantitative endpoints and quantitative parameters for characterizing cartilage morphology in OA.

The current imaging modality of choice in OA research is magnetic resonance imaging (MRI).  This can be used to assess the biochemical state of cartilage.  However, for registration studies with the FDA plain films have to be used, and we are also finding that there is more information about the disease in the plain films from just the basic joint space narrowing.

One of the problems with using MRI for this is that it is usually invasive and requires the injection of a contrast agent.  To overcome this, researchers have looked at the properties associated with sodium ions that are present in cartilage and have sought to develop MRI techniques that measure these. Researchers have, however, run into problems differentiating between sodium ions in cartilage and in the synovial fluid. Those problems appear to be have been solved by a team at NYU, in a recent paper published in the Journal of Magnetic Resonance.

In their paper on the use of sodium inversion recovery MRI of the knee joint in vivo at 7T, a team led by Alain Jerschow at NYU was able to isolate two pools of sodium ions and obtain images exclusively from cartilage tissue.

The technique uses a 7T MRI which is only available in research centers, rather than the more standard 3T magnet.  While this OA imaging technique could be useful for the elucidation of therapeutic effectiveness, I don’t think it is going to be too useful for the clinical diagnosis or management of a disease that is mainly driven by the symptoms.

However, I will be monitoring the progress of this research and its potential application to osteoarthritis clinical trials, in particular the cost/benefit compared to existing OA imaging techniques.

I look forward to reporting back from Brussels on the latest developments in OA imaging that are presented at OARSI. If you are attending the meeting, do let me know as I would be pleased to meet up if you have an interest in this area.

Sources:

  1. http://www.oarsi.org/meetings/10Congress/secondary.php?section=Preliminary_Program
  2. http://www.oarsi.org/
  3. chondrometrics.com/4613.html
  4. Madelin G, Lee J, Inati S, Jerschow A. Sodium inversion recovery MRI of the knee joint in vivo at 7T. JMR. Published online. Aug. 13, 2010. http://dx.doi.org/10.1016/j.jmr.2010.08.003

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Great #SCOPE2019 panel discussion today with industry veterans sharing ways sponsors and vendors can work together… https://t.co/U8j40R6y6R
Bioclinica (32 minutes ago)
RT @teaminspire: Patients Are Eager for Trials But Aren’t Getting the Word, Survey Finds https://t.co/BfLxhmpzZg via @CenterWatch #clinical…
Bioclinica (6 hours ago)
RT @DrugInfoAssn: Didn’t make it to #DIAEurope2019 in Vienna? Read highlights from @EFPIA here: https://t.co/I1XYJkTBha
Bioclinica (6 hours ago)
RT @CDISC: Introducing the CDISC Library https://t.co/KsGqdqIZBO. Join the CDISC Data Science team for two informational webinars to accomm…
Bioclinica (6 hours ago)
RT @PhillyCooke: Reminder that @RAPSorg Philly chapter networking mixer is March 7 at @DePuySynthes in West Chester. Register now: https://…
Bioclinica (7 hours ago)
RT @FDAWomen: #BlackHistoryMonth is also #HeartMonth. With 48% of African American women having a form of cardiovascular disease, it is tim…
Bioclinica (7 hours ago)

Latest Blogs:

Site Payments Solutions
Nonalcoholic steatohepatitis (NASH) development programs
Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box